The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.

doi:10.1158/1078-0432.CCR-11-2381

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Apr 2012

Shimizu Toshio, Tolcher Anthony W, Papadopoulos Kyriakos P, Beeram Muralidhar, Rasco Drew W, Smith Lon S, Gunn Shelly, Smetzer Leslie, Mays Theresa A, Kaiser Brianne, Wick Michael J, Alvarez Cathy, Cavazos Aracely, Mangold Gina L, Patnaik Amita

Abstract excerpt

PURPOSE: This study evaluated the clinical relevance of the dual-targeting strategy involving PI3K/AKT/mTOR and RAF/MEK/ERK pathways. EXPERIMENTAL DESIGN: We investigated safety, efficacy, and correlations between tumor genetic alterations and clinical benefit in 236 patients with advanced cancers treated with phase I study drugs targeting phosphoinositide 3-kinase (PI3K) and/or mitogen-activated protein kinase...

Topics

Adolescent
Adult
Aged
Aged, 80 and over
Extracellular Signal-Regulated MAP Kinases
Female
Humans
MAP Kinase Signaling System
Male

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Middle Aged

Molecular Targeted Therapy

Mutation

Neoplasms

Phosphatidylinositol 3-Kinases

Phosphoinositide-3 Kinase Inhibitors

Proto-Oncogene Proteins B-raf

Proto-Oncogene Proteins c-akt

Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed

Identifiers

PMID: 22261800
DOI: 10.1158/1078-0432.CCR-11-2381

Genes

BRAF
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 29 Aug 2026. Prepared record publication-22261800-2026-08-29.1. Manifest publication-graph-cohort-2026-08-29.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 29 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.PMID 22261800Read ↗

Rational Approaches for Combination Therapy Strategies Targeting the MAP Kinase Pathway in Solid TumorsSemantic proximity Read ↗

Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial.Semantic proximity Read ↗

Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapySemantic proximity Read ↗

Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy.Semantic proximity Read ↗

A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers.Semantic proximity Read ↗

Antitumor Activity in <i>RAS</i> -Driven Tumors by Blocking AKT and MEKSemantic proximity Read ↗

Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: in silico and biological evaluations.Semantic proximity Read ↗

Strategies and techniques for preclinical therapeutic targeting of PI3K in oncology: where do we stand in 2024?Semantic proximity Read ↗

PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects.Semantic proximity Read ↗

Toxicities from BRAF and MEK Inhibitors: Strategies to Maximize Therapeutic Success.Semantic proximity Read ↗

Prospects for personalized medicine with inhibitors targeting the RAS and PI3K pathways.Semantic proximity Read ↗

Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.